Robitussin DM is a popular over-the-counter medication used to treat coughs and colds. It contains two active ingredients: dextromethorphan, an antitussive that helps suppress coughs, and guaifenesin, an expectorant that helps thin and loosen mucus in the lungs. Robitussin DM is available in a variety of forms, including liquid, capsule, and tablet. While it is generally safe and effective when taken as directed, it is important to understand the proper dosage and potential side effects. This guide will provide an overview of Robitussin DM, including information about its uses, dosage, and potential side effects.
Robitussin DM is used to treat coughs and colds. The dextromethorphan in Robitussin DM helps suppress coughs, while the guaifenesin helps thin and loosen mucus in the lungs. Robitussin DM is available in a variety of forms, including liquid, capsule, and tablet. It is generally safe and effective when taken as directed.
Robitussin DM should be taken as directed on the package or as directed by a doctor. The recommended dose for adults and children over 12 years of age is two teaspoons (10 mL) every 4 to 6 hours, not to exceed 12 teaspoons (60 mL) in 24 hours. For children 6 to 12 years of age, the recommended dose is one teaspoon (5 mL) every 4 to 6 hours, not to exceed 6 teaspoons (30 mL) in 24 hours. For children under 6 years of age, Robitussin DM should not be used without consulting a doctor.
Robitussin DM is generally safe and effective when taken as directed. However, like all medications, it can cause side effects. Common side effects include nausea, vomiting, dizziness, drowsiness, and dry mouth. If these side effects persist or worsen, contact a doctor. Serious side effects are rare but can include difficulty breathing, chest tightness, and irregular heartbeat. If these side effects occur, seek medical help immediately.
Robitussin DM should not be taken by anyone who is allergic to any of its ingredients. It should also not be taken by anyone who has high blood pressure, heart disease, glaucoma, or an overactive thyroid. It should also not be taken by anyone who has taken a monoamine oxidase inhibitor (MAOI) in the past 14 days. Robitussin DM should not be taken by anyone who is pregnant or breastfeeding without consulting a doctor.
Robitussin DM can interact with certain medications, including MAOIs, sedatives, antidepressants, and other cough and cold medications. Before taking Robitussin DM, it is important to tell a doctor or pharmacist about all medications that are currently being taken.
Robitussin DM is a popular over-the-counter medication used to treat coughs and colds. It contains two active ingredients: dextromethorphan, an antitussive that helps suppress coughs, and guaifenesin, an expectorant that helps thin and loosen mucus in the lungs. Robitussin DM is generally safe and effective when taken as directed, but it is important to understand the proper dosage and potential side effects. This guide has provided an overview of Robitussin DM, including information about its uses, dosage, and potential side effects.
1.
Studies have shown that physical activity prevents cancer in patients who have been treated for cancer in the past.
2.
Glioblastoma treatment breakthrough shows promise
3.
Expert Q&A: A Drug Holiday for Metastatic Prostate Cancer?
4.
Marstacimab Gets FDA Nod for Hemophilia A or B Without Inhibitors
5.
Small-Town Patients Face Big Hurdles as Rural Hospitals Cut Cancer Care
1.
The Latest Research on Wiskott Aldrich Syndrome
2.
Uncovering the Hidden Signs: How to Recognize the Early Symptoms of Colon Cancer
3.
Transplant Oncology and Anti-Cancer Immunosuppressants: The Evolution of a Paradigm in Cancer Care
4.
Preventing Heparin Induced Thrombocytopenia: Tips for Successful Anticoagulation Therapy
5.
Bispecific Antibodies in Hematologic Malignancies: Mechanisms, Clinical Applications, and Future Directions
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV
2.
Current Scenario of Cancer- Final Discussion on the Importance of Genomic Testing & Advancement in Diagnosis and Treatment
3.
Efficient Management of First line ALK-rearranged NSCLC - Part V
4.
Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity
5.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation